Safe and effective methylphenidate therapy in a pediatric patient with glaucoma

American Academy of Pediatrics [AAP] Subcommittee on Attention-Deficit Hyperactivity Disorder and Committee on Quality Improvement (2001) Clinical practice guideline: treatment of the school-aged child with attention-deficit/hyperactivity disorder. Pediatrics 108(4):1033–1044

Aponte EP, Diehl N, Mohney BG (2010) Incidence and clinical characteristics of childhood glaucoma: a population-based study. Arch Ophthalmol 28(4):478–482

Bartik B, Harmon G, Kaplan F (1997) Use of methylphenidate therapy in a patient with glaucoma and attention-deficit hyperactivity disorder: a clinical dilemma. Arch Gen Psychiatry 54:188–189

Garnock-Jones KP, Keating GM (2009) Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents. Paediatr Drugs 11:203–226

Hieble JP, Ruffolo RR Jr (1997) Recent advances in the identification of alpha1- and alpha-2-adrenoceptor subtypes: therapeutic implications. Exp Opin Investig Drugs 6(4):367–387

Lu CK, Kuang TM, Chou JC (2006) Methylphenidate (Ritalin)-associated cataract and glaucoma. J Chin Med Assoc 69:589–590

Pliszka S (2007) Practice parameter for the assessment and treatment of children and adolescents with attention- deficit/hyperactivity disorder. J Am Acad Adolesc Psychiatry 46(7):894–921

Rappley M (2005) Attention deficit hyperactivity disorder. N Engl J Med 352:165–173

Reid WH, Blouin P, Schermer M (1976) A review of psychotropic medications and the glaucomas. Int Pharmacopsychiatry 11(3):163–174